SCHEMBL4158909

SCHEMBL4158909

CCN1C=Cc2cccc3cccc1c23

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.49
▸ MAPT P10636 7/20 0.49
▸ ALDH1A1 P00352 8/20 0.41
▸ HPGD P15428 7/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CASP1 P29466 2/20 0.41
▸ MPI P34949 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ APBA1 Q02410 1/20 0.41
▸ NSD2 O96028 8/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ GAA P10253 4/20 0.37
▸ CYP1B1 Q16678 1/20 0.37
▸ HSD17B10 Q99714 3/20 0.36
▸ APP P05067 1/20 0.36
▸ SNCA P37840 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8485186 0.81 KDM4E (0.34) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL15018068 0.80 HEXA (0.41) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL11797517 0.79 HEXA (0.40) KDM4EMAPTALDH1A1HPGDCASP1
SCHEMBL11881952 0.77 MAPT (0.53) KDM4EMAPTALDH1A1HPGDNSD2
SCHEMBL11790961 0.77 KDM4E (0.35) KDM4EMAPTALDH1A1HPGDNSD2
SCHEMBL1773296 0.77 NSD2 (0.46) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL15018437 0.76 HEXA (0.45) KDM4EMAPTALDH1A1HPGDNSD2
SCHEMBL15018655 0.76 NR1I2 (0.47) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL9776344 0.75 KDM4E (0.43) KDM4EMAPTALDH1A1HPGDSMN1; SMN2
SCHEMBL15018691 0.74 NPC1 (0.49) KDM4EMAPTALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710088-B2 Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2014-04-29 — — US disclosed
US-20090117040-A1 Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2009-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090117040-A1 Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases APP, PSEN2, PSEN1 KDM4E 4827/4885MAPT 10/4885ALDH1A1 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback